Clinically relevant doses of fluoxetine and reboxetine induce changes in the TrkB content of central excitatory synapses.
We have studied the effect of low doses of two widely used antidepressants, fluoxetine (Flx) and reboxetine (Rbx), on excitatory synapses of rat brain cortex and hippocampus. After 15 days of Flx treatment (0.67 mg/kg/day), its plasma level was 20.7+/-5.6 ng/ml. Analysis of postsynaptic densities (PSDs) by immunoblotting revealed no changes in the glutamate receptor subunits GluR1, NR1, NR2A/B, mGluR1alpha nor in the neurotrophin receptor p75(NTR). However, the brain-derived neurotrophic factor (BDNF) receptor TrkB decreased by 42.8+/-6%, and remained decreased after 6 weeks of treatment. The BDNF and TrkB content in homogenates of cortex and hippocampus began to rise at 9 and 15 days, respectively, and remained high for up to 6 weeks. Similar results were obtained following chronic Rbx administration at 0.128 mg/kg/day. We propose that BDNF, whose synthesis is increased by antidepressants, and which is in part released at synaptic sites, binds to TrkB in PSDs, leading to the internalization of the BDNF-TrkB complex and, thus, to a decrease of TrkB in the PSDs. This was paralleled by greater levels of phosphorylated (ie activated) TrkB in the light membrane fraction, that contains signaling endosomes. The retrograde transport of endocyted BDNF/TrkB complexes from spines to cell bodies, where it activates the synthesis of more BDNF, is a protracted process, potentially requiring several cycles of TrkB/BDNF complex endocytosis and transport. This positive feedback mechanism may help explain the time-lag between drug administration and its therapeutic effect, that is, the antidepressant drug paradox.
Neuroscience Laboratory, Faculty of Medicine, Universidad de los Andes, Casilla, Santiago, Chile.
Ursula
U
Wyneken
Mauricio
M
Sandoval
Soledad
S
Sandoval
Franscisco
F
Jorquera
Ignacio
I
González
Francisco
F
Vargas
Romina
R
Falcon
Milena
M
Monari
Fernando
F
Orrego
D000818:Animals; D000928:Antidepressive Agents / Q000097:blood / Q000494:pharmacology*; D015153:Blotting, Western / Q000379:methods; D001921:Brain / Q000166:cytology / Q000187:drug effects*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005473:Fluoxetine / Q000097:blood / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D047468:Immunoprecipitation / Q000379:methods; D008297:Male; D009025:Morpholines / Q000097:blood / Q000494:pharmacology*; D019000:Phosphotyrosine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077593:Reboxetine; D020813:Receptor, trkB / Q000378:metabolism*; D013347:Subcellular Fractions / Q000187:drug effects; D013569:Synapses / Q000187:drug effects*; D013997:Time Factors; D020696:rab5 GTP-Binding Proteins / Q000378:metabolism
D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor; D009025:Morpholines; D005473:Fluoxetine; D019000:Phosphotyrosine; D018698:Glutamic Acid; D000077593:Reboxetine; D020813:Receptor, trkB; D020696:rab5 GTP-Binding Proteins